Cargando…
Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy
BACKGROUND: Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatory markers in limited disease (LD) small-cell lung cancer (SCLC) patients undergoing thoracic chemoradiothe...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280890/ https://www.ncbi.nlm.nih.gov/pubmed/30555261 http://dx.doi.org/10.2147/CMAR.S180990 |
_version_ | 1783378756636770304 |
---|---|
author | Bernhardt, Denise Aufderstrasse, Sophie König, Laila Adeberg, Sebastian Bozorgmehr, Farastuk Christopoulos, Petros Shafie, Rami A El Hörner-Rieber, Juliane Kappes, Jutta Thomas, Michael Herth, Felix Steins, Martin Debus, Jürgen Rieken, Stefan |
author_facet | Bernhardt, Denise Aufderstrasse, Sophie König, Laila Adeberg, Sebastian Bozorgmehr, Farastuk Christopoulos, Petros Shafie, Rami A El Hörner-Rieber, Juliane Kappes, Jutta Thomas, Michael Herth, Felix Steins, Martin Debus, Jürgen Rieken, Stefan |
author_sort | Bernhardt, Denise |
collection | PubMed |
description | BACKGROUND: Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatory markers in limited disease (LD) small-cell lung cancer (SCLC) patients undergoing thoracic chemoradiotherapy (TCR). PATIENTS AND METHODS: We retrospectively analyzed a total number of 350 SCLC patients diagnosed with LD SCLC who received TCR between 1999 and 2017 and had available blood tests within 2 weeks prior to the start of TCR. Serum C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), hemoglobin (Hb) levels, and platelet count (Pc) were evaluated as potential inflammatory markers. Kaplan–Meier survival analysis was performed for overall survival (OS). For comparison of survival curves, the log-rank (Mantel–Cox) test was used. Univariate and multivariate Cox proportional HRs were used to assess the influence of cofactors on OS. RESULTS: Univariate analysis for OS revealed a statistically significant effect for LDH >400 U/L (HR 2.05 U/L; 95% CI 1.29–3.26 U/L; P=0.002), prophylactic cranial irradiation (PCI; HR 0.58; 95% CI 0.40–0.85; P=0.005), CRP >50 mg/L (HR 1.49 mg/L; 95% CI 1.05–2.10 mg/L; P=0.026), and Karnofsky performance scale (KPS) <70% (HR 1.35%; 95% CI 1.02–1.80%; P=0.035). NLR, age (>70 years), Hb levels, and Pc did not influence survival. In multivariate analysis, OS was significantly affected by PCI (HR 0.64; 95% CI 0.43–0.94; P=0.026), LDH >400 U/L (HR 1.91 U/L; 95% CI 1.21–3.05 U/L; P=0.006), and CRP >50 mg/L (HR 1.43 mg/L; 95% CI 1.01–2.04 mg/L; P=0.045). KPS (≤70%) did not influence survival in multivariate analysis. CONCLUSION: Elevated CRP and LDH seem to be the independent prognostic factors for OS in LD SCLC patients undergoing TCR. However, elevated NLR was not found to be an independent prognostic factor for OS if taken prior to TCR. LDH and CRP are easily available blood tests and do not require additional resources for routine use and could be useful for clinical decision making. |
format | Online Article Text |
id | pubmed-6280890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62808902018-12-14 Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy Bernhardt, Denise Aufderstrasse, Sophie König, Laila Adeberg, Sebastian Bozorgmehr, Farastuk Christopoulos, Petros Shafie, Rami A El Hörner-Rieber, Juliane Kappes, Jutta Thomas, Michael Herth, Felix Steins, Martin Debus, Jürgen Rieken, Stefan Cancer Manag Res Original Research BACKGROUND: Systemic inflammation appears to play a role in the progression of numerous solid tumors by promoting tumor proliferation. Our current study aimed to evaluate the role of inflammatory markers in limited disease (LD) small-cell lung cancer (SCLC) patients undergoing thoracic chemoradiotherapy (TCR). PATIENTS AND METHODS: We retrospectively analyzed a total number of 350 SCLC patients diagnosed with LD SCLC who received TCR between 1999 and 2017 and had available blood tests within 2 weeks prior to the start of TCR. Serum C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), hemoglobin (Hb) levels, and platelet count (Pc) were evaluated as potential inflammatory markers. Kaplan–Meier survival analysis was performed for overall survival (OS). For comparison of survival curves, the log-rank (Mantel–Cox) test was used. Univariate and multivariate Cox proportional HRs were used to assess the influence of cofactors on OS. RESULTS: Univariate analysis for OS revealed a statistically significant effect for LDH >400 U/L (HR 2.05 U/L; 95% CI 1.29–3.26 U/L; P=0.002), prophylactic cranial irradiation (PCI; HR 0.58; 95% CI 0.40–0.85; P=0.005), CRP >50 mg/L (HR 1.49 mg/L; 95% CI 1.05–2.10 mg/L; P=0.026), and Karnofsky performance scale (KPS) <70% (HR 1.35%; 95% CI 1.02–1.80%; P=0.035). NLR, age (>70 years), Hb levels, and Pc did not influence survival. In multivariate analysis, OS was significantly affected by PCI (HR 0.64; 95% CI 0.43–0.94; P=0.026), LDH >400 U/L (HR 1.91 U/L; 95% CI 1.21–3.05 U/L; P=0.006), and CRP >50 mg/L (HR 1.43 mg/L; 95% CI 1.01–2.04 mg/L; P=0.045). KPS (≤70%) did not influence survival in multivariate analysis. CONCLUSION: Elevated CRP and LDH seem to be the independent prognostic factors for OS in LD SCLC patients undergoing TCR. However, elevated NLR was not found to be an independent prognostic factor for OS if taken prior to TCR. LDH and CRP are easily available blood tests and do not require additional resources for routine use and could be useful for clinical decision making. Dove Medical Press 2018-11-30 /pmc/articles/PMC6280890/ /pubmed/30555261 http://dx.doi.org/10.2147/CMAR.S180990 Text en © 2018 Bernhardt et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Bernhardt, Denise Aufderstrasse, Sophie König, Laila Adeberg, Sebastian Bozorgmehr, Farastuk Christopoulos, Petros Shafie, Rami A El Hörner-Rieber, Juliane Kappes, Jutta Thomas, Michael Herth, Felix Steins, Martin Debus, Jürgen Rieken, Stefan Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
title | Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
title_full | Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
title_fullStr | Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
title_full_unstemmed | Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
title_short | Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
title_sort | impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280890/ https://www.ncbi.nlm.nih.gov/pubmed/30555261 http://dx.doi.org/10.2147/CMAR.S180990 |
work_keys_str_mv | AT bernhardtdenise impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT aufderstrassesophie impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT koniglaila impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT adebergsebastian impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT bozorgmehrfarastuk impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT christopoulospetros impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT shafieramiael impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT hornerrieberjuliane impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT kappesjutta impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT thomasmichael impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT herthfelix impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT steinsmartin impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT debusjurgen impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy AT riekenstefan impactofinflammatorymarkersonsurvivalinpatientswithlimiteddiseasesmallcelllungcancerundergoingchemoradiotherapy |